All In Biotech

Drug Trial Radar · NCT04809142

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

A Randomized, Open-label, Parallel Controlled, Multi-center Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Chemotherapy as Second-line Treatment in Subjects With Advanced Biliary Cancer

Last checked: Nov 19, 2026Latest source record: Mar 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 392 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

392

Planned (sponsor's estimate)

Start

Feb 4, 2021

Primary completion

Mar 18, 2022

Study completion Feb 1, 2023

Sponsor

Sponsor type
Industry
First posted
Mar 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus chemotherapy as second-line treatment in subjects with advanced biliary cancer.

Conditions

  • Advanced Biliary Cancer

Interventions

  • TQB2450 InjectionDrug

    TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.

  • Anlotinib hydrochlorideDrug

    Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

  • Oxaliplatin injectionDrug

    Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;

  • Capecitabine tabletsDrug

    Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;

  • Gemcitabine hydrochloride injectionDrug

    Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: up to 40 weeks

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincal Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Beijing Chao-Yang Hospital,Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Youan Hospital,Captical Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China · Not yet recruiting

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China · Not yet recruiting

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China · Not yet recruiting

  • Harbin Medical University Affiliated Tumor Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Henan Tumor Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Tongji Medical College of HUST

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Provincial People's Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The First Peoples Hospital of Changzhou

    Changzhou, Jiangsu, China · Not yet recruiting

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.